Evidence map›Paper›PMID 42640736›Full record

ArticleThe Journal of clinical investigation2026

MANF clears mutant uromodulin in human kidney organoids of autosomal dominant tubulointerstitial kidney disease.

Chenjian Gu, Yili Fang, Yixuan Wang, Eric Tycksen, Gayathri Kondepati, Chuang Li, Kendrah O Kidd, Jun Liu, Fumihiko Urano, Maria Lindahl and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Chenjian GuDepartment of Medicine.
Yili FangDepartment of Medicine.
Yixuan WangInstitute of Materials Science and Engineering, and.
Eric TycksenGenome Technology Access Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Gayathri KondepatiInstitute of Materials Science and Engineering, and.
Chuang LiDepartment of Medicine.
Kendrah O KiddDepartment of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.
Jun LiuShanghai General Hospital, Shanghai, China.
Fumihiko UranoDepartment of Medicine.
Maria LindahlUniversity of Helsinki, Helsinki, Finland.
Anthony J BleyerDepartment of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.
Srikanth SingamaneniInstitute of Materials Science and Engineering, and.
Zhao SunDepartment of Biological Sciences, The University of Texas at Dallas, Richardson, Texas, USA.
Ying Maggie ChenDepartment of Medicine.

Funding

Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Resource Based Center for Musculoskeletal Biology and Medicine (Overall Application)P30AR074992 · NIAMS · WASHINGTON UNIVERSITY · PI MATTHEW J SILVA · 2019 to 2026
$6.8M
The Role of the Osteoblast Secretome in Bone FormationP30AR057235 · NIAMS · WASHINGTON UNIVERSITY · PI SILVA, MATTHEW J · 2009 to 2018
$5.7M
PODOCYTE ENDOPLASMIC RETICULUM STRESS AND NEPHROTIC SYNDROMER01DK105056 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2017 to 2025
$4.5M
Mutant Laminin Chains and Nephrotic SyndromeK08DK089015 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2010 to 2014
$641k
Ultrabright Plasmonic-Fluor Nanosensor-Enabled Noninvasive Management of Pediatric Nephrotic SyndromeR21DK131557 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE, SINGAMANENI, SRIKANTH · 2022 to 2022
$236k
Develop Autophagy Activators to Treat Autosomal Dominant Tubulointerstitial Kidney DiseaseR56DK138158 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2024 to 2024
$200k
PHARMACOLOGICAL RESCUE OF MUTANT LAMININ IN NEPHROTIC SYNDROMER03DK106451 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2015 to 2016
$153k
BLRD VA I01 BX006401NIAMS NIH HHS P30 AR057235NIAMS NIH HHS P30 AR074992NIDDK NIH HHS K08 DK089015NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R01 DK105056NIDDK NIH HHS R03 DK106451NIDDK NIH HHS R21 DK131557NIDDK NIH HHS R56 DK138158
6 · The paper itself

Abstract

In human kidney organoids, MANF treats genetic kidney disease ADTKD-UMOD by blocking ER calcium leakage and restoring autophagy to clear the toxic mutant protein.

Indexed as

AutophagyKidneyMutationOrganoidsUromodulinEndoplasmic ReticulumHumansUMOD protein, humanUromodulinAutophagyCalcium signalingGeneticsMolecular geneticsNephrology

Identifiers

PMID42640736
PMCPMC13668634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.